Should You Buy Verano Holdings Corp. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Verano Holdings Corp. (VRNO) carries a solid Quality of Company rating of 5.7/10. Trading at $5.85, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 1 of 2 CirclFi valuation models project upside for Verano Holdings Corp. (VRNO) at $5.85 — the models are evenly split, with a Quality Score of 5.7/10 and Value-Trap risk of 38/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Verano Holdings Corp. (VRNO) in 2026?
What Is the Bull Case vs the Bear Case for Verano Holdings Corp. (VRNO)?
| Bull case — $18.48 target (+215.8%) | Bear case — $4.41 target (-24.6%) |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +95.6% across 1 bullish models from the current price of $5.85. | According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model sees the stock as overvalued with a fair value of $4.41 (-24.6%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the PWERM model targets a fair value of $18.48 (+215.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +240.5% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: therapeutic area leadership could provide meaningful support for Verano Holdings Corp.'s revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: drug pricing legislation represents a meaningful risk for Verano Holdings Corp. and its Drug Manufacturers - Specialty & Generic peers. |
How Does VRNO Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: RMTI · TLPH · TKNO · BFRI · BIOA · YCBD · CBIH · HLN · ADCT · UTHR · AMPH
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like VRNO on Quality?
Closest companies to VRNO’s Quality of Company score of 5.7/10, across all industries.
- QURT — Quarta-Rad, Inc. (QOC 5.7) · analysis
- CARV — Carver Bancorp, Inc. (QOC 5.7) · analysis
- MFBI — Monroe Federal Bancorp, Inc. (QOC 5.7) · analysis
- GFLT — GenFlat Holdings, Inc. (QOC 5.7) · analysis
- AAPG — Ascentage Pharma Group Internat (QOC 5.7) · analysis
- FTRE — Fortrea Holdings Inc. (QOC 5.7) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does VRNO Appear In?
So Is Verano Holdings Corp. (VRNO) Worth Buying in 2026?
Our models don't have a clear verdict on Verano Holdings Corp.. At $5.85 vs. $11.44 median fair value, the median upside of +95.6% masks significant model disagreement (+240.5% spread). With quality at 5.7/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Verano Holdings Corp.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About VRNO Stock?
Should I buy VRNO stock right now?
Based on CirclFi's multi-model analysis, 1 of 2 models see upside for VRNO at $5.85. The models are divided, which means the investment case depends heavily on your assumptions about Verano Holdings Corp.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Verano Holdings Corp.?
Key risks include: limited model coverage (2/13 active), reducing analytical confidence; wide model disagreement (319% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does VRNO compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, VRNO holds a Quality Score of 5.7/10. Comparable companies include RMTI (QOC 5.8), TLPH (QOC 5.7), TKNO (QOC 5.8). The relative ranking helps investors identify whether VRNO offers better fundamental quality than alternatives in the same sector.
Is VRNO a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. VRNO's Quality Score of 5.7/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy VRNO at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $4.41 to $18.48. At $5.85, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for VRNO.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad